Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system

Journal of Urology

Volumn 168, Issue 6, 2002, Pages 2659-2664

  Yoshimura, Ichiro ^a   Ikegami, Shusei ^a   Suzuki, Satoshi ^a   Tadakuma, Takushi ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Gene therapy; Prodrugs; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

CRE RECOMBINASE; CYTOSINE DEAMINASE; FLUCYTOSINE; LUCIFERASE; PRODRUG; PROSTATE SPECIFIC ANTIGEN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA RECOMBINATION; ENHANCER REGION; GENE ACTIVITY; GENE AMPLIFICATION; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 0036895176     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64239-5     Document Type: Article

References (18)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1999. CA Cancer J Clin, 49: 8, 1999
2. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J. et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756, 1996
3. Palapattu, G. S., Naitoh, J. and Belldegrun, A. S.: Gene therapy for prostate cancer. New perspectives on an old problem. Urol Clin North Am, 26: 353, 1999
4. Moolten, F. L.: Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther, 1: 279, 1994
5. Gotoh, A., Ko, S. C., Shirakawa, T., Cheon, J., Kao, C., Miyamoto, T. et al: Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol, 160: 220, 1998
6. Latham, J. P., Searle, P. F., Mautner, V. and James, N. D.: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res, 60: 334, 2000
7. Stricklett, P. K., Nelson, R. D. and Kohan, D. E.: The Cre/loxP system and gene targeting in the kidney. Am J Physiol, 276: f651, 1999
8. Nagayama, Y., Nishihara, E., Iitaka, M., Namba, H., Yamashita, S. and Niwa, M.: Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res, 59: 3049, 1999
9. Ueda, K., Iwahashi, M., Nakamori, M., Nakamura, M., Matsuura, I., Yamaue, H. et al: Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/5-fluorocytosine enhanced by the cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res, 61: 6158, 2001
10. Suzuki, S., Tadakuma, T., Asano, T. and Hayakawa, M.: Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res, 61: 1276, 2001
11. Mullen, C. A., Kilstrup, M. and Blaese, R. M.: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA, 89: 33, 1992
12. Becker, T. C., Noel, R. J., Coats, W. S., Gomez-Foix, A. M., Alam, T., Gerard, R. D. et al: Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol, 43: 161, 1994
13. Zhang, W. W., Koch, P. E. and Roth, J. A.: Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques, 18: 444, 1995
14. Springer, C. J. and Niculescu-Duvaz, I.: Prodrug-activating systems in suicide gene therapy. J Clin Invest, 105: 1161, 2000
15. Rchuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G. and Henderson, D. R.: Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem, 271: 7043, 1996
16. Pang, S., Dannull, J., Kaboo, R., Xie, Y., Tso, C. L., Michel, K. et al: Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res, 57: 495, 1997
17. Watt, F., Martorana, A., Brookes, D. E., Ho, T., Kingsley, E., O'Keefe, D. S. et al: A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics, 73: 243, 2001
18. Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gonczol, E. and Wilson, J. M.: Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA, 91: 4407, 1994